INTRODUCTION
============

Chagas disease is a neglected tropical disease ([@b32-jer-14-5-844]) endemic in regions with scarce resources and with significant increase in prevalence in countries with large numbers of immigrants ([@b13-jer-14-5-844]). Chagas heart disease (CHD) is the clinical form with the worst prognosis ([@b10-jer-14-5-844]; [@b27-jer-14-5-844]), defined by the presence of characteristic abnormalities of myocardial damage at electrocardiogram and/or echocardiogram, with or without left ventricular dysfunction ([@b2-jer-14-5-844]; [@b10-jer-14-5-844]). The cardiac involvement leads to skeletal and cardiac muscles abnormalities ([@b20-jer-14-5-844]), changes in lung function ([@b4-jer-14-5-844]), inspiratory muscle weakness ([@b4-jer-14-5-844]; [@b30-jer-14-5-844]), poor quality of life ([@b29-jer-14-5-844]), and reduced functional capacity ([@b4-jer-14-5-844]; [@b18-jer-14-5-844]), which should be regularly evaluated.

Patients with CHD may have functional impairment even in the presence of preserved left ventricular ejection fraction (LVEF) ([@b18-jer-14-5-844]), and the cardiopulmonary exercise testing (CPET) is the gold standard in the assessment of physical function ([@b15-jer-14-5-844]). The peak oxygen uptake (peak VO~2~) and the minute ventilation-carbon dioxide production slope (VE/VCO~2~ slope) can be directly measured by gas analysis and provide important clinical and prognostic information ([@b15-jer-14-5-844]; [@b25-jer-14-5-844]). Nevertheless, the CPET is expensive and usually not available in endemic areas, limiting its applicability in clinical routine. Therefore, submaximal tests such as the 6-min walk test (6MWT) and the incremental shuttle walk test (ISWT) ([@b7-jer-14-5-844]) may be simple and inexpensive approaches to the functional assessment of patients with CHD.

The 6MWT is widely used in patients with CHD ([@b9-jer-14-5-844]; [@b8-jer-14-5-844]; [@b11-jer-14-5-844]). The test is easy to perform, inexpensive and well tolerated by patients ([@b3-jer-14-5-844]). It has good reliability, moderate validity and ability to predict functional capacity in patients with heart failure ([@b7-jer-14-5-844]; [@b23-jer-14-5-844]). However, the 6MWT is distance-limited, self-paced, and patients tend to select a comfortable speed ([@b21-jer-14-5-844]), which could underestimate the functional evaluation.

Unlike the 6MWT, the ISWT is a symptom-limited test, with progressive increment of workload ([@b22-jer-14-5-844]; [@b28-jer-14-5-844]). The regular increments make the test more similar to the CPET, and strong correlations are usually found between distance walked and VO~2~ peak in patients with different diseases, including heart failure ([@b21-jer-14-5-844]; [@b22-jer-14-5-844]) and CHD ([@b1-jer-14-5-844]).

Despite the common application of these tests in cardiac rehabilitation, no study was found that compared these measures in patients with CHD. Considering that Chagas cardiomiopathy is the most fibrosing and arrhythmogenic of known heart diseases and, consequently, with a worse prognosis ([@b6-jer-14-5-844]; [@b26-jer-14-5-844]), it is necessary to verify the performance of exercise testing in patients with Chagas cardiomyopathy. So, the present study aimed to compare the 6MWT and the ISWT measures in patients with CHD and to determine the accuracy of these field tests in the identification of functional impairment.

MATERIALS AND METHODS
=====================

This cross-sectional study was conducted at a referral center in the management of infectious and parasitic diseases. The research was carried out in accordance with the Declaration of Helsinki ([@b33-jer-14-5-844]) and was approved by the institutional ethics committee (approval number: CAAE 03993912. 6.0000.5149). All the patients were informed about the objectives and agreed to voluntarily participate in the study.

Study design
------------

The sample included CHD patients with different degrees of cardiac involvement. Eligibility criteria included the positive serology for *Trypanosoma cruzi* and the presence of arrhythmias and intraventricular and atrioventricular conduction disorders with or without left ventricular dysfunction (compatible with CHD) ([@b2-jer-14-5-844]). Patients with cardiopathy by any other causes, with comorbidities and unable to perform the exercise tests were excluded.

On the first day, the participants underwent clinical evaluation, echocardiography and CPET. The 6MWT and ISWT were performed on the following two days. A maximum interval of one week was allowed among the exercise tests. The investigators were blinded to the test results.

Echocardiographic evaluation
----------------------------

Echocardiography was performed according to recommendations of the American Society of Echocardiography ([@b16-jer-14-5-844]) by one investigator who was blinded to the clinical evaluation of the patients. LVEF was obtained by modified Simpson rule. Early diastolic velocity (e′) at the medial border of the mitral annulus was obtained and the ratio between peak mitral E and e′ (E/e′) was calculated.

Cardiopulmonary exercise testing
--------------------------------

The CPET was performed on a treadmill with the metabolic analysis system MetaLyzer 3B (Cortex Medical, Leipzig, Germany). The peak VO~2~ and minute ventilation-carbon dioxide production (VE/VCO~2~) slope were used as the primary endpoints in functional evaluation and obtained according to current guidelines ([@b14-jer-14-5-844]).

6-min walk test
---------------

The 6MWT was guided by American Thoracic Society guidelines ([@b3-jer-14-5-844]). During the 6MWT, the volunteers had to walk at the highest possible speed, without running, in a 30-m corridor. Words of encouragement were used every minute. Two tests were applied, with 15-min interval between them and the primary endpoint was the longest 6MWT distance, expressed in meters.

Incremental shuttle walk test
-----------------------------

The ISWT was performed using the protocol proposed by [@b28-jer-14-5-844]. The test was applied in a 10-m course corridor marked out by two cones nine meters apart. The minimum speed achieved by patients on the test was controlled by signals from an audiotape previously recorded in regular intervals. The test was finished when the volunteer completed the 12 levels or could not achieve the distance target between cones within the intervals for two consecutive times. The primary endpoint was the longest ISWT distance, expressed in meters.

Statistical analysis
--------------------

Statistical analyses were performed using SPSS ver. 17.0 (SPSS Inc., Chicago, IL, USA). Continuous data were expressed as mean and standard deviation and median and interquartile range, as appropriate. Categorical variables were shown as absolute number and percentage. Difference between distances walked during 6MWT and ISWT was verified by the Wilcoxon signed-rank test. Correlations were evaluated by Pearson or Spearman correlation test. The significance level was set at 5%. The agreement analysis between distances walked during submaximal field tests was verified by the Bland--Altman graph and the differences values were plotted against their mean. A ROC curve was constructed to verify the accuracy of 6MWT and ISWT in identifying those patients with peak VO~2~ below 20 mL/kg/min functional impairment, defined as values according to Webber classification ([@b31-jer-14-5-844]). The statistical difference between the curves was determined by chi-square using the software MedCalc version 13.1.2.0 (MedCalc Software, Ostend, Belgium).

RESULTS
=======

Patients with CHD (n=35) were evaluated and the characteristics of the sample are shown in [Table 1](#t1-jer-14-5-844){ref-type="table"}.

No significant difference was found between the distances traveled (*P*=0.694). The agreement between the distances walked during field tests is demonstrated in the Bland--Altman diagram ([Fig. 1](#f1-jer-14-5-844){ref-type="fig"}). Only one pair (2.8%) lies outside the limits of agreement.

As shown in [Fig. 2](#f2-jer-14-5-844){ref-type="fig"}, significant correlation of peak VO~2~ was observed both with the 6MWT distance (*r*=0.577, *P*\<0.001) and with the ISWT distance (*r*=0.587, *P*\<0.001). The VE/VCO~2~ slope correlated only with ISWT distance (*r*=−0.339, *P*=0.003).

The area under the ROC curve showed that the distance walked during the 6MWT and the ISWT can identify patients with functional impairment (area under the curve \[AUC\], 0.77; 95% confidence interval \[CI\], 0.61--0.93 and AUC, 0.87; 95% CI, 0.75--0.99, respectively). The optimal cut point value for 6MWT and ISWT to identify functional impairment was a distance less than 520 m and 400 m, respectively. The sensibility and specificity for this cutoff value were, respectively, 75% and 71% for 6MWT distance and 80% and 86% for ISWT distance. As shown in [Fig. 3](#f3-jer-14-5-844){ref-type="fig"}, there was no significant difference between the areas under the curves (*P*=0.276).

DISCUSSION
==========

To the best of our knowledge, this is the first study that compared the 6MWT and ISWT distance and CPET variables in CHD patients with mild cardiac involvement. The main findings are (a) the good agreement between the 6MWT and ISWT distance, (b) the significant correlations between the 6MWT and ISWT distance and peak VO~2~ as well as between ISWT distance and VE/VCO~2~, and (c) the good accuracy of both field tests in the identification of patients with functional impairment.

[@b21-jer-14-5-844] analyzed the association between the 6MWT and the ISWT with peak VO~2~ (CPET) in 46 patients (53± 10 years, NYHA 2.8±0.7). They found that the correlation between the ISWT and peak VO~2~ was stronger (*r*=0.83, *P*\<0.001) than the 6MWT (*r*=0.69, *P*\<0.001). However, the present study found that the correlation between 6MWT and ISWT distance with peak VO~2~ were similar.

Another study ([@b24-jer-14-5-844]) verified the association between the 6MWT and ISWT distances and peak VO~2~ in heart failure patients (n=63, 51.3±10.2 years, NYHA II--IV), with 25% of the sample being composed by patients with CHD. The authors verified both the 6MWT and ISWT had strong correlations with peak VO~2~ (*r*=0.76 and *r*=0.79, respectively). They also found significant difference between the distances traveled during the submaximal field tests (*P*\<0.001), unlike the present study.

Most of patients in the present study were in NYHA functional class I and with preserved LVEF, which can partially explain the differences. We believe that field tests can underestimate the maximal functional capacity in patients with mild cardiac impairment. During the 6MWT, patients tend to select a comfortable speed, even if they can walk faster. In the ISWT, many of the patients with good functional capacity can reach the maximum level of the test (level 12), which occurred in the present study with 20% of the sample. However, patients rarely reached the maximum level of the CPET. Therefore, it appears that both field tests can be applied in the evaluation of functional capacity in CHD patients with good correlation with peak VO~2~, regardless of the degree of cardiac involvement. However, we recommend caution with this statement as a result of the small sample evaluated.

Our results also demonstrated that ISWT distance correlated weakly with VE/VCO~2~ slope. This may have clinical relevance, since VE/VCO~2~ slope is the only variable assessed by CPET considered an independent predictor of survival in CHD patients ([@b25-jer-14-5-844]). Indeed, survival data are not available in the present study, which is a limitation for the analysis of predictive validity, and the prognostic value of ISWT distance should be investigated in longitudinal studies.

Additionally, the present study verified that both field tests have good accuracy in the identification of CHD patients with functional impairment, without significant difference between the areas under the ROC curve. The cutoff points of distance walked with good sensitivity and specificity in identifying patients with functional impairment may be useful in the risk stratification of patients and in the adoption of preventive management based on physical exercise. Previous studies ([@b21-jer-14-5-844]; [@b24-jer-14-5-844]) also reported the effectiveness of 6MWT and ISWT in identifying patients with heart failure and severely reduced peak VO~2~, showing cutoff values of 380 for ISWT and 490 for 6MWT ([@b24-jer-14-5-844]) or 450 for both ([@b21-jer-14-5-844]).

These results have important clinical meaning in the setting of CHD, since the endemic areas are generally poor, and the maximal exercise test may not be available. Furthermore, emerging studies have shown that exercise training can be beneficial to patients with Chagas disease ([@b12-jer-14-5-844]; [@b17-jer-14-5-844]; [@b19-jer-14-5-844]) and field tests can also aid in risk stratification, which is very important for directing patients to cardiac rehabilitation ([@b5-jer-14-5-844]). Therefore, both 6MWT and ISWT may be helpful in the functional evaluation and risk management of patients with CHD.

In conclusion, the 6MWT and the ISWT provide similar measures for assessment of the functional capacity in patients with mild CHD. Both field tests, inexpensive and easy-to-perform, can identify patients with functional impairment and have potential value for the assessment of patients with CHD in resource-limited areas.
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Characteristics of the sample (n=35)

  Variable                         Value
  -------------------------------- ----------------------
  Characterization of the sample   
   Age (yr)                        47.1±8.2
   Male sex                        23 (66)
   Body mass index (kg/m^2^)       26.5±4.6
   NYHA functional class           
    I                              20 (57)
    II                             09 (26)
    III                            06 (17)
                                   
  Echocardiographic variable       
   LVEF (%)                        59.0 (41.0--64.0)
   LVDD (mm)                       55.7±11.5
   E/e' ratio                      12.2±4.2
                                   
  Functional variable              
   Peak VO~2~ (mL/kg/min)          26.3±8.1
   VE/VCO~2~ slope                 31.9±4.2
   6MWT distance (m)               571.0±81.7
   ISWT distance (m)               437.9 (329.0--658.2)
   ISWT level reached              
    Level 5--8                     23 (66)
    Level 9--11                    5 (14)
    Level 12                       7 (20)

Values presented as mean±standard deviation, number (%), or median (interquartile range).

NYHA, New York Heart Association functional class; LVEF, left ventricular ejection fraction; LVDd, left ventricular end-diastolic diameter; E/e′ ratio, ratio of the early diastolic transmitral flow velocity to early diastolic mitral annular velocity; peak VO~2~, peak oxygen uptake; VE/VCO~2~, minute ventilation-carbon dioxide production; 6MWT, 6-min walk test; ISWT, incremental shuttle walk test.
